Literature DB >> 15128279

Effect of heparin administration to sheep on the release profiles of circulating activin A and follistatin.

Kristian L Jones1, David M De Kretser, David J Phillips.   

Abstract

Activin A and follistatin are normally present in relatively low amounts in the circulation. Heparin administration elicits a rapid and robust release of these proteins, although this phenomenon is poorly defined. In the present studies, the response to heparin administration was evaluated in the plasma of adult ewes in terms of whether it was dose-dependent, could be neutralized, was responsive to multiple stimulation, and the nature of the activin A and follistatin released. Activin A and follistatin were rapidly released by heparin in a dose-dependent manner (25, 100 or 250 IU/kg), with differences in the response as adjudged by peak concentration, timing of the peak and area under the curve. The heparin response could be blocked by pretreatment with protamine; conversely protamine injection alone (2 mg/kg) elicited release of follistatin but not activin A. Repeat administration of heparin at three-hourly intervals resulted in activin and follistatin responses to each injection, but each subsequent stimulation increased and extended the responses, consistent with saturation of the heparin clearance mechanism. Size exclusion chromatography of plasma samples confirmed that the majority of activin and follistatin released by heparin was a complex, whereas follistatin released by protamine was unbound. These data are consistent with a large pool of activin A and follistatin resident on extracellular matrices, with the rapid response implicating the vascular endothelium as the prime site of release following administration of these commonly used anticoagulant therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128279     DOI: 10.1677/joe.0.1810307

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Activin and transforming growth factor-beta signaling pathways are activated after allergen challenge in mild asthma.

Authors:  Harsha H Kariyawasam; Sophie Pegorier; Julia Barkans; Georgina Xanthou; Maxine Aizen; Sun Ying; A Barry Kay; Clare M Lloyd; Douglas S Robinson
Journal:  J Allergy Clin Immunol       Date:  2009-09       Impact factor: 10.793

2.  Whole genome expression analysis reveals differential effects of TiO2 nanotubes on vascular cells.

Authors:  Lily Peng; Andrea J Barczak; Rebecca A Barbeau; Yuanyuan Xiao; Thomas J LaTempa; Craig A Grimes; Tejal A Desai
Journal:  Nano Lett       Date:  2010-01       Impact factor: 11.189

3.  Follistatin and the Breast Implant Capsule.

Authors:  Brett A Frenkiel; Peter Temple-Smith; David de Kretser; Graeme J Southwick
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-03-01

4.  Substantial Increases Occur in Serum Activins and Follistatin during Lung Transplantation.

Authors:  David M de Kretser; Jonathan G Bensley; David J Phillips; Bronwyn J Levvey; Greg I Snell; Enjarn Lin; Mark P Hedger; Robyn E O'Hehir
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

5.  Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.

Authors:  Andrea Iskenderian; Nan Liu; Qingwei Deng; Yan Huang; Chuan Shen; Kathleen Palmieri; Robert Crooker; Dianna Lundberg; Niksa Kastrapeli; Brian Pescatore; Alla Romashko; John Dumas; Robert Comeau; Angela Norton; Jing Pan; Haojing Rong; Katayoun Derakhchan; David E Ehmann
Journal:  Skelet Muscle       Date:  2018-10-27       Impact factor: 4.912

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.